Three-year growth response to growth hormone treatment in very young children born small for gestational age-data from KIGS
Related Experiment Video
Updated: Apr 30, 2026

Breast Milk Enhances Growth of Enteroids: An Ex Vivo Model of Cell Proliferation
Published on: February 15, 2018
Margaret C S Boguszewski1, Anders Lindberg, Hartmut A Wollmann
1Department of Pediatrics (M.C.S.B.), Federal University of Paraná, Curitiba PR 80060-900, Brazil; Pfizer Inc (A.L.), Endocrine Care, SE-190 91 Sollentuna, Sweden; and Pfizer Inc (H.A.W.), Endocrine Care, 10117 Berlin, Germany.
Insights
Growth hormone (GH) treatment significantly improves height and weight in very young children born small for gestational age (SGA). The existing prediction model for older SGA children accurately estimates growth response in these younger patients.
Area of Science:
- Pediatric Endocrinology
- Growth and Development
- Clinical Research
Background:
- Children born small for gestational age (SGA) often experience persistent short stature.
- Early growth failure in SGA children can impact adult height.
Purpose of the Study:
- To assess the 3-year growth outcomes of growth hormone (GH) therapy in very young SGA children.
- To validate prediction models for GH treatment response in SGA children aged 2-6 years.
Main Methods:
- Utilized data from the Pfizer International Growth Database (KIGS).
- Analyzed growth response in 620 SGA children (birth size <-2 SDS) treated with GH.
- Compared outcomes in two age groups: 2-4 years (n=156) and 4-6 years (n=464).
Main Results:
- Both age groups showed significant increases in height and weight standard deviation scores (SDS) after 3 years of GH treatment (P < .01).
- Median height SDS improved from -3.9 to -2.2 in the younger group and -3.4 to -2.0 in the older group.
- Median weight SDS also significantly increased in both groups.
Conclusions:
- GH treatment is effective in improving height and weight in very young SGA children lacking spontaneous catch-up growth.
- Established prediction models for SGA children accurately estimate growth response in this younger cohort.
Context:
Children born small for gestational age (SGA) with poor growth during the first years of life may remain short in stature during childhood and as adults.
Objective:
To evaluate the 3-year growth response to GH treatment in very young short children born SGA, and to test the existing predictions models for growth response developed for older SGA children.
Setting:
KIGS (The Pfizer International Growth Database).
Patients:
A total of 620 SGA children (birth length and/or weight below -2 SD score [SDS]) on GH treatment, 156 in the 2- to 4-year-old group (100 boys; median age, 3.3 y), and 464 in the 4- to 6-year-old group (284 boys; median age, 4.9 y).
Results:
Median values and 10th-90th percentiles are presented. Both groups presented a significant increase in height velocity during GH treatment. Median height SDS increased from -3.9 (-5.4 to -2.9) at the start to -2.2 (-3.8 to -1.0) at 3 years in the 2- to 4-year-old group (P < .01) and from -3.4 (-4.5 to -2.6) to -2.0 (-3.3 to -0.9) in the 4- to 6-year-old group (P < .01). Median weight SDS increased from -3.8 (-5.9 to -2.4) to -2.1 (-4.1 to -0.5) in the 2- to 4-year-old group (P < .01). Respective values for the 4- to 6-year-old group were -3.1 (-4.8 to -1.8) to -1.6 (-3.1 to -0.1) SDS (P < .01). First- and second-year growth response could be estimated by the SGA model.
Conclusion:
Very young children born SGA without spontaneous catch-up growth presented a significant improvement in height and weight during the 3 years of GH treatment. Growth response could be estimated by the SGA model.
Related Concept Videos
Nature and Nurture
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Oxygen Requirements and Growth Patterns
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Drug Dosing: Infants and Children

